Gender Male
Andrew focuses on investments in therapeutics and medical devices.
Prior to joining H.I.G., Andrew was the Director of Pharmaceutical Sciences at the Clinton Health Access Initiative, where he led several product development programs and managed strategic research collaborations. Andrew began his investment career at Tang Capital Management
where he served as a Principal, supporting public and private investments in the biotech space. He later joined Citadel Investment Group's Global Equities team, as a therapeutics and medtech analyst. Previously, Andrew was a Business Development Manager for Genzyme Cardiovascular and helped successfully shepherd a major clinical in-licensing program.
Andrew earned a BSE in Mechanical Engineering from Princeton University, an MD from Harvard Medical School and a PhD in Bioengineering from M.I.T.
